Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial - PubMed (original) (raw)
Clinical Trial
. 2017 Mar;76(3):405-417.
doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
Affiliations
- PMID: 28057360
- DOI: 10.1016/j.jaad.2016.11.041
Free article
Clinical Trial
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
Andrew Blauvelt et al. J Am Acad Dermatol. 2017 Mar.
Free article
Abstract
Background: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.
Objectives: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year.
Methods: Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 weeks; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47; n = 334). Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported outcomes (Dermatology Life Quality Index, Psoriasis Symptoms and Signs Diary), and safety were evaluated through week 48.
Results: Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]). Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%). Furthermore, guselkumab significantly improved patient-reported outcomes through week 48. Adverse event rates were comparable between treatments.
Limitations: Analyses were limited to 48 weeks.
Conclusions: Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.
Keywords: VOYAGE 1; VOYAGE 2; adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis.
Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Clinical Trial. - Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA. Armstrong AW, et al. Am J Clin Dermatol. 2019 Feb;20(1):155-164. doi: 10.1007/s40257-018-0396-z. Am J Clin Dermatol. 2019. PMID: 30417277 Free PMC article. Clinical Trial. - A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. Gordon KB, et al. N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646. N Engl J Med. 2015. PMID: 26154787 Clinical Trial. - Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Al-Salama ZT, Scott LJ. Al-Salama ZT, et al. Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1. Am J Clin Dermatol. 2018. PMID: 30467781 Review. - A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
Nawas Z, Hatch M, Ramos E, Liu M, Tong Y, Peranteau A, Tyring S. Nawas Z, et al. Skin Therapy Lett. 2017 Mar;22(2):8-10. Skin Therapy Lett. 2017. PMID: 28329405 Review.
Cited by
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.
Jauregui W, Abarca YA, Ahmadi Y, Menon VB, Zumárraga DA, Rojas Gomez MC, Basri A, Madala RS, Girgis P, Nazir Z. Jauregui W, et al. Cureus. 2024 Sep 3;16(9):e68569. doi: 10.7759/cureus.68569. eCollection 2024 Sep. Cureus. 2024. PMID: 39364475 Free PMC article. Review. - Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review.
Khan M, Wallace CE, Ahmed F, Rahman SM, Memon N, Haque A. Khan M, et al. J Psoriasis Psoriatic Arthritis. 2024 Apr;9(2):61-68. doi: 10.1177/24755303231217491. Epub 2023 Nov 18. J Psoriasis Psoriatic Arthritis. 2024. PMID: 39295894 Free PMC article. Review. - Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.
Marcelli L, Belcastro A, Talamonti M, Paganini C, Fico A, Savastano L, Di Raimondo C, Vellucci L, Bianchi L, Galluzzo M. Marcelli L, et al. J Clin Med. 2024 Aug 31;13(17):5175. doi: 10.3390/jcm13175175. J Clin Med. 2024. PMID: 39274388 Free PMC article. - IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis.
Aggarwal P, Fleischer AB Jr. Aggarwal P, et al. J Clin Med. 2024 Aug 29;13(17):5139. doi: 10.3390/jcm13175139. J Clin Med. 2024. PMID: 39274352 Free PMC article. - Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
Blauvelt A, Chen Y, Branigan PJ, Liu X, DePrimo S, Keyes BE, Leung M, Fakharzadeh S, Yang YW, Muñoz-Elías EJ, Krueger JG, Langley RG. Blauvelt A, et al. JID Innov. 2024 Jun 26;4(5):100297. doi: 10.1016/j.xjidi.2024.100297. eCollection 2024 Sep. JID Innov. 2024. PMID: 39224116 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical